- Home
- MSFT vs XOMAP Comparison
MSFT vs XOMAP Comparison
Compare MSFT & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSFT
- XOMAP
- Stock Information
- Founded
- MSFT 1975
- XOMAP N/A
- Country
- MSFT United States
- XOMAP United States
- Employees
- MSFT N/A
- XOMAP 13
- Industry
- MSFT Computer Software: Prepackaged Software
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- MSFT Technology
- XOMAP Health Care
- Exchange
- MSFT Nasdaq
- XOMAP Nasdaq
- Market Cap
- MSFT N/A
- XOMAP N/A
- IPO Year
- MSFT 1986
- XOMAP N/A
- Fundamental
- Price
- MSFT $429.03
- XOMAP $25.32
- Analyst Decision
- MSFT Strong Buy
- XOMAP
- Analyst Count
- MSFT 30
- XOMAP 0
- Target Price
- MSFT $511.07
- XOMAP N/A
- AVG Volume (30 Days)
- MSFT 19.0M
- XOMAP N/A
- Earning Date
- MSFT 01-29-2025
- XOMAP N/A
- Dividend Yield
- MSFT 0.77%
- XOMAP N/A
- EPS Growth
- MSFT 17.35
- XOMAP N/A
- EPS
- MSFT 12.11
- XOMAP N/A
- Revenue
- MSFT $254,190,000,000.00
- XOMAP N/A
- Revenue This Year
- MSFT $15.84
- XOMAP N/A
- Revenue Next Year
- MSFT $14.23
- XOMAP N/A
- P/E Ratio
- MSFT $35.43
- XOMAP N/A
- Revenue Growth
- MSFT 16.44
- XOMAP N/A
- 52 Week Low
- MSFT $385.58
- XOMAP N/A
- 52 Week High
- MSFT $468.35
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- MSFT 51.24
- XOMAP 38.15
- Support Level
- MSFT $410.72
- XOMAP $25.82
- Resistance Level
- MSFT $434.32
- XOMAP $25.52
- Average True Range (ATR)
- MSFT 7.61
- XOMAP 0.10
- MACD
- MSFT -0.13
- XOMAP -0.03
- Stochastic Oscillator
- MSFT 74.73
- XOMAP 3.23
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.